Biocross

Biocross develops non-invasive, blood-based diagnostic tools for the early detection and monitoring of neurodegenerative and metabolic diseases. Its primary products, e4Risk and e4Quant, identify and quantify the ApoE4 protein biomarker to assess risk for Alzheimer’s disease, Type 2 Diabetes, and cardiovascular conditions. These CE-certified tests are designed for use in hospital settings to provide neurologists with cost-effective alternatives to traditional diagnostic methods.